Dec 2025 $4 M Private placement after listing $2 to $10 million 5
Lexaria Bioscience Corp.: Private sale, Dec 2025 × Investors in this round 5 investors had bought by the notice of Dec 19, 2025: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $245,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice John Docherty · Executive Officer, Director Michael Shankman · Executive Officer Richard Christopher · Executive Officer, Director ALBERT Edward REESE · Director Bal Edward Bhullar · Director Christopher Bunka · Director Nicholas Baxter · Director William Edward McKechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. WAINWRIGHT & CO. (CRD 375) · New York, New York Sold in FL, IL, NY Remarks in the notice On fees: “Sales commission represents 7% of the gross proceeds received from the sale of registered shares and unregistered warrants”On the amounts: “Offering amount represents gross proceeds from the sale of shares registered under an S-3 Registration Statement and the associated non-registered warrants”Signed by Richard Christopher, Ceo. Source: SEC Form D, newest notice filed Dec 19, 2025. Read the notice at the SEC .
options SEC Sep 2025 $4 M Private placement after listing $2 to $10 million 5
Lexaria Bioscience Corp.: Private sale, Sep 2025 × Investors in this round 5 investors had bought by the notice of Oct 1, 2025: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $280,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice John Docherty · Executive Officer, Director Michael Shankman · Executive Officer Richard Christopher · Executive Officer, Director Albert Edward Reese · Director Bal Edward Bhullar · Director Christopher Bunka · Director Nicholas Baxter · Director William Edward McKechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. WAINWRIGHT & CO. (CRD 375) · New York, New York Sold in IL, NY, and outside the US Remarks in the notice On fees: “Commission represents 7% of the offering amount, including for the registered shares that form part of the combined offering of 1 registered share and 1 unregistered warrant”Signed by Richard Christopher, Ceo. Source: SEC Form D, newest notice filed Oct 1, 2025. Read the notice at the SEC .
options SEC Oct 2024 $5 M Private placement after listing $2 to $10 million 1
Lexaria Bioscience Corp.: Private sale, Oct 2024 × Investors in this round 1 investor had bought by the notice of Oct 16, 2024: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $350,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice John Docherty · Executive Officer, Director Michael Shankman · Executive Officer Richard Christopher · Executive Officer Albert Reese · Director Catherine Turkel · Director Christopher Bunka · Director Nicholas Baxter · Director Ted Mckechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. WAINWRIGHT & CO. (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “Commission represents 7% of the offering amount”On the amounts: “Offering Amount is for the shares that were issued as registered securities, the unregistered warrants from part of the offering”Signed by Richard Christopher, Ceo. Source: SEC Form D, newest notice filed Oct 16, 2024. Read the notice at the SEC .
options SEC Feb 2024 $4 M Private placement after listing $2 to $10 million 2
Lexaria Bioscience Corp.: Private sale, Feb 2024 × Investors in this round 2 investors had bought by the notice of Feb 16, 2024: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $222,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Christopher Bunka · Executive Officer, Director John Docherty · Executive Officer, Director Albert Reese · Director Catherine Turkel · Director Nicholas Baxter · Director Ted Mckechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. WAINWRIGHT & CO. (CRD 375) · New York, New York Sold in IL, NY Signed by Christopher Bunka, Ceo. Source: SEC Form D, newest notice filed Feb 16, 2024. Read the notice at the SEC .
options SEC Oct 2023 $2 M Private placement after listing Under $2 million 1
Lexaria Bioscience Corp.: Private sale, Oct 2023 × Investors in this round 1 investor had bought by the notice of Oct 4, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $109,879
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Christopher Bunka · Executive Officer, Director John Docherty · Executive Officer, Director Albert Reese · Director Catherine Turkel · Director Nicholas Baxter · Director Ted Mckechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round MAXIM GROUP LLC (CRD 120708) · New York, New York Sold in NY Remarks in the notice On fees: “"Maxim Group LLC (""Maxim""), acted as the placement agent in connection with the offering. Maxim received an aggregate fee equal to 5% of the gross proceeds of the offering."”On the amounts: “The combined effective offering price of each warrant which was combined with a registered share of common stock or a pre-funded warrant in lieu was $0.97, or aggregate gross proceeds of approximately $1.5 million”Signed by Christopher Bunka, Ceo. Source: SEC Form D, newest notice filed Oct 4, 2023. Read the notice at the SEC .
options SEC Dec 2021 $1 M Private placement after listing Under $2 million 1
Lexaria Bioscience Corp.: Private sale, Dec 2021 × Investors in this round 1 investor had bought by the notice of Dec 20, 2021: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Christopher Bunka · Executive Officer, Director Gregory Downey · Executive Officer John Docherty · Executive Officer, Director Albert Reese · Director Nicholas Baxter · Director Ted Mckechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Chris Bunka, Chief executive officer. Source: SEC Form D, newest notice filed Dec 20, 2021. Read the notice at the SEC .
equity SEC May 2020 $2 M Private placement after listing $2 to $10 million 21
Lexaria Bioscience Corp.: Private sale, May 2020 × Investors in this round 21 investors had bought by the notice of May 13, 2020: 20 accredited, 1 not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $151,623
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Allan Spissinger · Executive Officer Christopher Bunka · Executive Officer, Director John Docherty · Executive Officer, Director Brian Quigley · Director Nicholas Baxter · Director Ted McKechnie · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Bradley Woods & Co. Ltd. (CRD 13660) · New York, New York Sold in CA, CT, IL, NY, PA, WI, and outside the US Remarks in the notice On fees: “In addition to the sales commission,the Company issued to the placement agent and its designees Warrants to purchase up to 649,123 shares of common stock and shall, subject to certain exceptions, pay 8% of the proceeds received from warrant exercises.”Signed by Christopher Bunka, Ceo. Source: SEC Form D, newest notice filed May 13, 2020. Read the notice at the SEC .
equity, options SEC